I bet that the fed stays on the sidelines with same old rhetoric
and an emphasis to corp debt concerns.
It doesn't make sense for them to make a move because these were the levels
around the time that the rate hike was being priced in.
Hedge individual stocks both long and short to manage risks.
I've been short SPY on avg .290 but I'm taking profits off...
If 200 DMA slope starts to point downward, this will be a cold summer for stocks.
Short term, 260
Long term bet 185
Let's say we get to 3k or 31k or even 35k, the faster we deviate from the norm,
the sharper the downfall, so my bet is on the downside
I'm long from today's low of 198, May 31 Expiration 207C. Let's see if it can get more bounce on Musk exercising 175,000 shares.
If it fails, then hedge somewhere, no biggie. I do have a feeling it'll go down more due to big money pulling out (T Rowe Price dumped)
and all the downgrades PLUS who's to say it won't be affected by the trade war with China.
250 is possible IF SOMEONE SCREWS UP ON THE POLITICAL AND MACROECONOMIC side of things! --- but come hell or high water $320 is price target before or after reporting Q1.
Not a fan of the disrespect to the SEC, not here to pick fights, but the crap that they give TSLA has gone way too far. SIZE UP!
“If you look at what Tesla has done, if you look at their volume...
1.) Average age of consumers are 75+, only 10% of its sales come from medicare. <---- UNACCEPTABLE
2.) WRONG INFO GIVEN BY RESELLERS TO CUSTOMERS.
Citron estimates that Inogen sells about 90% of its POC units vs. only renting about 10% through Medicare. Assuming 40% of POC units were rented through Medicare, Inogen’s revenue would decline by about...
Buckingham Research cautious
Shares of Whirlpool are up 7% over the last 90 days after an extended slide when tariff-related price hikes cut into consumer demand for products. -by Clark Schultz, SA News
BAML expects appliance volume to decline
Clearly, that Dec 24 route was the clear buying opportunity, You would've been +40% by now.
Is it too late? I'd say NO.
If you have the ability to invest on this, and of course, have an awareness on all the geopolitical factors. I think this is a win.
If you want to swing, it's also up to you.
Here's the thing
1) Let's be clear, DexCom is the leader on CGM...
SAGE has been on its own phase the last 2 trading days.
Jan 7 - announced Phase 3 success of SAGE-217 for postpartum depression; same day AXS-05 for MDD was reported.
Both drugs are being compared to each other for the future MDD treatment; promising (as usual).
Axsome is a low hanging fruit with a higher volume but I do like how SAGE moves. I'll have...
Those who have the ability to ignore the noise and the roller coaster ride that the markets have brought upon us from early October to this day, you would be +80% on $ARGX. Nevertheless, if you were/are trading/playing it, it's a good play.
Whether it's politics or economics, there's way too many factors in play so all things are considered, -awareness for the...
- By insider
Chairman & CEO of Medtronic Plc (MDT) Omar Ishrak bought 12,000 shares of MDT on 01/09/2019 at an average price of $84.05 a share. The total cost of this purchase was $1 million.
I'm long from $82.61. Follow the $. Set stops.
long entry from $100; PT1 $125 PT2 $143
Q1 2019 - FDA meeting outcome on Sativex;
Sativex (nabiximols) is an oromucosal spray of a formulated botanical extract of cannabis
that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio
Approved in >25 countries outside of the U.S. for the treatment of spasticity...
Q4 Pullback was expected, not a big deal; Stock price elevated because of news and same old pump and dump. Epidiolex didn't ship until November 1st.
3 Positive Phase 3 from Sativex - FDA meeting for regulatory pathway to U.S. expected in December.
Resumed @ Piper Jaffray on Nov 5th as overweight; The Street updated to sell after the drop; Market edge on...
Net income increased by 191.5% when compared to the same quarter one year prior, rising from $6.37 million to $18.57 million.
Net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Technology industry.
The Street - Buy
Credit Suisse - Outperform
Market Edge - Long
Zacks - Strong Buy
Short Float - 1.18%